trending Market Intelligence /marketintelligence/en/news-insights/trending/thM-9tjntseRkiMy1IkKIg2 content esgSubNav
In This List

UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

UCB SA's psoriatic arthritis drug bimekizumab significantly improved joint and skin symptoms in a phase 2b trial.

Psoriatic arthritis is an inflammatory condition affecting the joints and skin.

The study met its primary goal with up to 46% of psoriatic arthritis patients who received the treatment seeing at least 50% improvement in joint symptoms after 12 weeks, compared with 7% of patients on placebo.

Among patients with skin lesions, 65% of those who received the drug experienced at least 90% skin clearance at week 12, compared with 7% who received placebo.

Bimekizumab has also demonstrated its efficacy in treating ankylosing spondylitis, a type of arthritis that mainly affects the spine. In a phase 2b study, 47% of patients receiving bimekizumab achieved at least 40% improvement in disease symptoms, compared to 13% receiving placebo after 12 weeks.